Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy - Seite 3
For further information, please contact
Idorsia Media & Investor Relations
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
www.idorsia.com
Contact: Neurocrine Biosciences, Inc.
Navjot Rai (Media)
858-617-7623
media@neurocrine.com
Todd Tushla (Investors)
858-617-7143
ir@neurocrine.com
Idorsia Forward-Looking Statements
The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates",
"believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or
intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products
expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company
with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be
materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.
Neurocrine Biosciences Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to,
statements related to the benefits to be derived from the agreement with Idorsia and the timing of completion of our clinical, regulatory, and other development activities. Among the factors that
could cause actual results to differ materially from those indicated in the forward-looking statements are: risks that the FDA or other regulatory authorities may make adverse decisions regarding
ACT-709478; risks that clinical development activities may not be completed on time or at all or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate
previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical
trials; risks that the benefits of the agreement with Idorsia may never be realized; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission,
including without limitation the Company's quarterly report on Form 10-Q for the quarter ended September 30, 2019. Neurocrine disclaims any obligation to update the statements contained in this
press release after the date hereof.
Attachment